Literature DB >> 28360708

Tardive Blepharospasm and Meige Syndrome during Treatment with Quetiapine and Olanzapine.

Ayça Kiliç1, Evrim Erten2, Armağan Özdemir2.   

Abstract

Meige syndrome, which has been presented in tardive syndromes, is a form of blepharospasm accompanied by oromandibular dystonia with manifestations over the face, jaw, and neck. A blepharospasm can be induced by antihistamines, dopaminomimetic or sympathomimetic drugs, or long-term exposure to dopamine antagonists. Atypical antipsychotics have less extrapyramidal side effects because of a weak dopamine D2 receptor binding affinity or a strong antagonistic effect to serotonin 5-HT2a receptor and have been known to cause less tardive dyskinesia than typical antipsychotics. Thus, in literature, atypical antipsychotics are recommended for the treatment of psychosis in cases of tardive dyskinesia. The potential risk factors associated with the development of tardive dyskinesia are extrapyramidal symptoms' history, diabetes mellitus, affective disorder, female gender, older age, and long-term therapy with neuroleptics at higher dosages. As reported below, a patient with an affective disorder who had quetiapine-induced oromandibular dystonia and olanzapine-induced Meige syndrome after antipsychotic augmentation in different stages of the disease process was presented.

Entities:  

Keywords:  Atypical antipsychotics; Meige syndrome; tardive blepharospasm; tardive dyskinesia

Year:  2015        PMID: 28360708      PMCID: PMC5353202          DOI: 10.5152/npa.2015.7411

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  19 in total

1.  Tardive dyskinesia associated with olanzapine monotherapy.

Authors:  J Ananth; J Kenan
Journal:  J Clin Psychiatry       Date:  1999-12       Impact factor: 4.384

2.  A case of Meige dystonia induced by short-term quetiapine treatment.

Authors:  Tadashi Nishikawa; Satoko Nishioka
Journal:  Hum Psychopharmacol       Date:  2002-06       Impact factor: 1.672

Review 3.  Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.

Authors:  Vladimir Lerner; Chanoch Miodownik
Journal:  Curr Psychiatry Rep       Date:  2011-08       Impact factor: 5.285

4.  Marked improvement of Meige's syndrome with olanzapine in a schizophrenic patient.

Authors:  Hiroki Fukui; Toshiya Murai
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2002       Impact factor: 2.198

5.  Blepharospasm associated with olanzapine: a case report.

Authors:  E Shimizu; A Otsuka; K Hashimoto; M Iyo
Journal:  Eur Psychiatry       Date:  2004-09       Impact factor: 5.361

6.  Venlafaxine and tardive blepharospasm: a case report.

Authors:  Yu Lee; Wei-Chiang Yeh; Mian-Yoon Chong; Pao-Yen Lin; Yung-Yee Chang
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-03-30       Impact factor: 5.067

7.  Treatment of patients with tardive dystonia with olanzapine.

Authors:  Claudio Lucetti; Giovanna Bellini; Angelo Nuti; Silvia Bernardini; Grazia Dell'Agnello; Armando Piccinni; Luca Maggi; Laura Manca; Ubaldo Bonuccelli
Journal:  Clin Neuropharmacol       Date:  2002 Mar-Apr       Impact factor: 1.592

8.  Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.

Authors:  Scott W Woods; Hal Morgenstern; John R Saksa; Barbara C Walsh; Michelle C Sullivan; Roy Money; Keith A Hawkins; Ralitza V Gueorguieva; William M Glazer
Journal:  J Clin Psychiatry       Date:  2010-02-09       Impact factor: 4.384

9.  Tardive blepharospasm.

Authors:  P Sachdev
Journal:  Mov Disord       Date:  1998-11       Impact factor: 10.338

10.  The course of tardive dystonia in Afro Caribbean patients, a population-based study: the Curacao extrapyramidal syndromes study: VII.

Authors:  P N van Harten; G E Matroos; J Van Os
Journal:  Schizophr Res       Date:  2007-10-23       Impact factor: 4.939

View more
  1 in total

1.  Refractory dry eye disease associated with Meige's syndrome induced by long-term use of an atypical antipsychotic.

Authors:  Ji Eun Kim; Ji Won Jung
Journal:  BMC Ophthalmol       Date:  2020-12-02       Impact factor: 2.209

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.